CDNA earnings call summary

准备环节要点

• 第四季度总营收 1.084亿美元，同比增长 25%（CEO）
• 检测服务营收 7,840万美元，同比增长 23%，检测量约 53,000次，同比增长 17%（CFO）
• 患者与数字解决方案营收 1,680万美元，同比增长 47%（CFO）
• 实验室产品营收 1,330万美元，同比增长 17%（CFO）
• 非GAAP毛利率 68.5%（CFO）；全年毛利率 69.3%，同比持平（CFO）
• 第四季度调整后EBITDA 650万美元（同比下降34%）；全年调整后EBITDA 3,170万美元（同比增长14%）（CFO）
• 第四季度现金收款 1.158亿美元，同比增长 37%；全年现金收款 4.056亿美元，同比增长 32%（

Q&A Batch (1-5 of 5)

Q1 — Brandon Couillard

• Topic: Volume guidance and Patient & Digital Solutions break-out
• Key points:
  • 2026 volume guidance of 12% growth does not assume any increase in transplant procedural volume.
  • Epic Aura lift is too early to quantify; mgmt expects to provide guidance on the longer-term impact by the Q2 call after ~6 months of integration with 10+ sites.
  • Product, Patient & Digital Solutions collectively guided to 8–12% growth in 2026; mgmt notes these businesses outperformed every quarter in 2025.
  • Software margins in the mid-60s (60–70%); product margins in the 50–60% range, with mgmt working on taking manufacturing in-house to normalize margins.
• Mgmt stance: Neutral-to-bullish – conservative volume assumption but high hopes for Digital/Product upside; margin improvement initiatives underway.

Q2 — Vivian

• Topic: Revenue guidance build, LCD headwind, and SHORE manuscript update
• Key points:
  • Revenue midpoint = $432M, with a $12M band. Testing volume midpoint = 224k tests (12% YoY), with a band of 220k–228k tests (10–14% growth).
  • LCD impact: $7.5M revenue reduction built into guidance (negative $33 per test at midpoint). Out-of-period revenue recognition: $5.0M ($22 per test positive).
  • Testing revenue per test midpoint = ~$1,410, ±$20. Gross margin midpoint = 70% (range 69–71%). Quarterly OpEx midpoint = $68M, ±$1M.
  • Adjusted EBITDA guide: $30M–$45M, includes $9M depreciation add-back. LCD expected to be finalized mid-2026 (June–July timeframe).
  • SHORE-3 manuscript data was included in the comment letter; published data shared with MolDX.
• Mgmt stance: Cautious – conservative range-bound assumptions built, with LCD headwind explicitly modeled; mgmt hopes to beat revenue per test midpoint.

Q3 — Tycho Peterson

• Topic: Epic integration investment, $2,000 reimbursement target, and Elohim commercial readiness
• Key points:
  • Internal 3-year goal to achieve a $2,000/test average reimbursement (above current guide).
  • Spending ~$10M to upgrade and integrate with Epic (Aura + Enterprise) across six lab information systems; ~$6M of that is recurring, $4M one-time implementation.
  • Integration is expected to take ~18 months (phased approach). Mgmt believes it won’t require a heavy lift to offset the ~$6M recurring cost through volume lifts and cleaner claims.
  • For Elohim (cell therapy), activities include: submit SHORE-3 manuscript, educate clinicians, complete CLIA readiness, submit for reimbursement by end of fiscal year – targeting revenue and coverage in 2028.
• Mgmt stance: Bullish – Epic integration seen as enabling higher reimbursement and volume; disciplined spending to offset costs; Elohim timeline clear and progressing.

Q4 — Andrew Brackman

• Topic: Digital Solutions growth drivers and capital allocation
• Key points:
  • Testing Services Q4 2025 growth of 17% YoY attributed to solution-selling under Chief Commercial Officer Jessica.
  • Digital growth driven by MedActionPlan

Q&A Batch (6-7 of 7)

Q6 — Andrew Cooper

• Topic: 增长来源分布与EBITDA利润率指引
• Key points:
  • 增长在监测（surveillance）和事件驱动（for-cause）测试间相对均匀分布；2024年《自然医学》论文推动了AlloSure在肾移植事件驱动场景中的使用。
  • 即使加回400万美元一次性支出（1000万美元投资的一部分），2026年指引中点EBITDA利润率略低于10%。
  • 管理层的内部模型：若营收为4.4亿美元、次年增长15%，增量毛利润的50%将转化为EBITDA。
  • 管理层重申将于2027年达到20% EBITDA利润率目标，并引用Veracyte曾达28%作为参照。
• Mgmt stance: 看涨（重申长期20% EBITDA利润率目标，认为当前销售团队加速投资是阶段性举措，不会持续多年）。

Q7 — Mason Carrico

• Topic: 测试量指引与肾移植协议采纳的驱动因素
• Key points:
  • 2026年指引基于三类增长来源：现有已采纳协议的中心仍有大量利用空间（如患者漏检、医嘱未开等）；事件驱动测试持续增长；仍有更多新协议可争取。
  • 管理团队未提供已采纳协议中心占肾移植总量的百分比，称无实时数据。
• Mgmt stance: 看涨（强调现有中心利用不足、事件驱动趋势延续、新协议持续开拓三项因素共同支撑指引）。